Trial
NCT03605212
Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults
Phase ITERMINATEDREGULATORYConfidence: MEDIUM
Sponsor
Menarini Group
Collaborators
—
Condition
Tumor Lysis Syndrome
Intervention
Febuxostat
Why stopped
The study was stopped as per EMA waiver granted on 20July2018.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-03